๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› ESCC
Clinical trial register · China

ESCC Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 4 Shanghai 3 Guangzhou 2 Hefei 1 Guanzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin4 Shanghai3 Guangzhou2 Hefei1 Guanzhou1
All 7 locations
Target enrolment
to

ESCC trials in China

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07701681ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University
Phase 2
75
Guangzhou
2026-08-31
Recruiting
Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)
NCT07627347ESCC
Nanfang Hospital, Southern Medical University
Not applicable
25
Guangzhou
2026-05-18
Not yet open
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
NCT07531979ESCC, Tislelizumab, Chemotherapy, Becotatug Vedotin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
93
Tianjin
2026-04-01
Not yet open
TAS-102 Plus Radiotherapy in Elderly ESCC
NCT07196345ESCC, TAS 102, Radiotherapy
Qianfoshan Hospital
Phase 1/2
45
Jinan
2025-09-25
Recruiting
AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
NCT06489197ESCC, Advanced Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2024-11-16
Not yet open
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
NCT06531291ESCC, Biliary Tract Cancer, Gastric Cancer, Pancreas Cancer
RenJi Hospital
Phase 2
80
Shanghai
2024-08-10
Recruiting
Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma
NCT07050576ESCC, Lymph Node Metastasis, Radiomics
The First Affiliated Hospital of Anhui Medical University
Observational
500
Hefei
2024-05-01
Recruiting
Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
NCT06698692ESCC
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2024-04-02
Recruiting
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
NCT04686682NSCLC, SCLC, CRPC, ESCC
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
152
Tianjin
2021-05-07
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/escc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition ESCC.

How many ESCC trials are recruiting in China?

6 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (ESCC), 13 studies
PhaseStudiesRecruitingShare
Phase 28261.5%
Observational2215.4%
Phase 1/22115.4%
Not applicable117.7%

Most active sponsors

Lead sponsors with the most studies (ESCC)
Lead sponsorStudiesRecruiting
Tianjin Medical University Cancer Institute and Hospital31
Jacobio Pharmaceuticals Co., Ltd.11
Nanfang Hospital, Southern Medical University11
Qianfoshan Hospital10
RenJi Hospital10
Sixth Affiliated Hospital, Sun Yat-sen University11
Sun Yat-sen University10
Tan Lijie10
The First Affiliated Hospital of Anhui Medical University11
The First Affiliated Hospital with Nanjing Medical University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.